• Revenue and EBITDA: Piramal Pharma posted a 72% jump in Q1 EBITDA on broad-based demand and 17% revenue growth, but management retained its full-year FY27 revenue growth guidance at mid-teens due to macroeconomic volatility.
• Leverage and CapEx: Net debt-to-EBITDA currently stands at 3.7 times on a trailing 12-month basis, with plans to cap leverage at this level while continuing CapEx on expanding the Lexington sterile injectables facility and the Riverview ADC suite.
• Canalog brand integration: Commercial supplies for the acquired Canalog brand from BMS will commence in Q2 FY27, generating revenue and turning margin accretive immediately despite long-term integration requirements.
• Consumer health performance: Consumer products power brands grew 23%, with e-commerce expanding 40% to contribute nearly 30% of sales, while single-digit segment profitability is targeted for gradual improvement.
• Impairments and cost pressures: The company confirmed that no further intangible asset impairments are expected after last quarter's ₹176 crore write-down, while rising prices for petrol, solvents, and plastics are being actively managed.